Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, has an excellent tolerability profile when given in single doses of up to 16-fold the therapeutic dose

被引：0

作者：

Bias, P ^{[1
]}

Buchner, A ^{[1
]}

Lammerich, A ^{[1
]}

机构：

[1] Merckle GMBH, Clin Res, Ulm, Germany

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：479 / 479

页数：1

共 10 条

[1] Licofelone, A 5-LOX, COX-1 and COX-2 inhibitor, has excellent hepatic tolerability in patients with symptomatic OA of the knee
Bias, P
Buchner, A
Schulz, U
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 366 - 367
[2] Licofelone, a 5-LOX, COX-1 and COX-2 inhibitor or the treatment of osteoarthritis, has equivalent efficacy and improved tolerability compared with naproxen
Buchner, A
Bias, P
Lammerich, A
Schulz, U
OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S25 - S25
[3] Licofelone a 5-LOX, COX-1 and COX-2 inhibitor is as effective as naproxen and has improved GI tolerability in patients with osteoarthritis.
Bias, P
Buchner, A
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S72 - S72
[4] Licofelone a 5-LOX, COX-1 and COX-2 inhibitor is as effective as celecoxib and shows better tolerability in patients with osteoarthritis of the knee.
Pavelka, K
Bias, P
Buchner, A
Lammerich, A
Schulz, U
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S73 - S73
[5] Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with osteoarthritis of the knee
Pavelka, K
Bias, P
Buchner, A
Lammerich, A
Schulz, U
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 261 - 261
[6] Evaluation of effects of licofelone, an inhibitor of COX-1, COX-2 and 5-LOX on platelet function in an in vitro model of thrombosis with circulating human blood
Hernández, M
Tonda, R
Pedreño, J
Arderiu, G
Pino, M
Serradell, M
Escolar, G
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 263 - 263
[7] Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee
Blanco, FJ
Buchner, A
Bias, P
Lammerich, A
Schulz, U
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 262 - 262
[8] Twice the therapeutic dose of licofelone - An inhibitor of COX-1, COX-2 and 5-LOX - Results in a significantly lower GI ulcer incidence than naproxen in OA patients, when administered with or without concomitant low-dose aspirin
Buchner, A
Bias, P
Lammerich, A
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 261 - 261
[9] Licofelone, A 5-LOX, COX-1 and COX-2 inhibitor, is as effective as celecoxib over 12 weeks of treatment: OARSI/OMERACT-OARSI response criteria results
Buchner, A
Bias, P
Schulz, U
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 366 - 366
[10] Licofelone -: an inhibitor of 5-LOX, COX-1 and COX-2 has superior GI tolerability in OA patients compared with naproxen, regardless of low-dose aspirin co-medication, previous ulcer history or H-pylori status.
Bias, P
Buchner, A
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S72 - S72

← 1 →